JP2018076331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018076331A5 JP2018076331A5 JP2017231391A JP2017231391A JP2018076331A5 JP 2018076331 A5 JP2018076331 A5 JP 2018076331A5 JP 2017231391 A JP2017231391 A JP 2017231391A JP 2017231391 A JP2017231391 A JP 2017231391A JP 2018076331 A5 JP2018076331 A5 JP 2018076331A5
- Authority
- JP
- Japan
- Prior art keywords
- synthetic nanocarrier
- osmotic
- pharmaceutical composition
- mediated release
- release barrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002539 nanocarrier Substances 0.000 claims 41
- 238000000034 method Methods 0.000 claims 30
- 230000003204 osmotic effect Effects 0.000 claims 18
- 230000001404 mediated effect Effects 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000002552 dosage form Substances 0.000 claims 12
- 108091034117 Oligonucleotide Proteins 0.000 claims 7
- 239000013543 active substance Substances 0.000 claims 6
- 150000001720 carbohydrates Chemical class 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000013612 plasmid Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 231100000317 environmental toxin Toxicity 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 229920002292 Nylon 6 Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000000137 annealing Methods 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000004581 coalescence Methods 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000005515 coenzyme Substances 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 231100000573 exposure to toxins Toxicity 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 150000002678 macrocyclic compounds Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000004633 polyglycolic acid Substances 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 150000004043 trisaccharides Chemical class 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467595P | 2011-03-25 | 2011-03-25 | |
| US61/467,595 | 2011-03-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502642A Division JP6320912B2 (ja) | 2011-03-25 | 2012-03-23 | 浸透圧媒介性放出合成ナノ担体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018076331A JP2018076331A (ja) | 2018-05-17 |
| JP2018076331A5 true JP2018076331A5 (enExample) | 2018-10-11 |
Family
ID=46877545
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502642A Active JP6320912B2 (ja) | 2011-03-25 | 2012-03-23 | 浸透圧媒介性放出合成ナノ担体 |
| JP2017231391A Pending JP2018076331A (ja) | 2011-03-25 | 2017-12-01 | 浸透圧媒介性放出合成ナノ担体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502642A Active JP6320912B2 (ja) | 2011-03-25 | 2012-03-23 | 浸透圧媒介性放出合成ナノ担体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20120244222A1 (enExample) |
| EP (1) | EP2694040A4 (enExample) |
| JP (2) | JP6320912B2 (enExample) |
| KR (1) | KR20140022025A (enExample) |
| CN (1) | CN103458879A (enExample) |
| AU (2) | AU2012236937B2 (enExample) |
| BR (1) | BR112013024655A2 (enExample) |
| CA (1) | CA2830948A1 (enExample) |
| EA (1) | EA201391392A1 (enExample) |
| MX (1) | MX366228B (enExample) |
| WO (1) | WO2012135010A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0639059B2 (ja) | 1985-11-08 | 1994-05-25 | キヤノン株式会社 | 光導電部材用基体の製造装置 |
| JP2706993B2 (ja) | 1988-11-25 | 1998-01-28 | キヤノン株式会社 | 光導電部材用基体の製造装置 |
| WO2010138193A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| AU2010293059B2 (en) * | 2009-08-26 | 2017-03-16 | Selecta Biosciences, Inc. | Compositions that induce T cell help |
| US20110293700A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
| CN103501812A (zh) | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| CN109172819A (zh) | 2011-07-29 | 2019-01-11 | 西莱克塔生物科技公司 | 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体 |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| AU2013243949A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| CA2910584A1 (en) | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells |
| EP3041934A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| KR102507624B1 (ko) | 2013-11-22 | 2023-03-09 | 미나 테라퓨틱스 리미티드 | Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법 |
| US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
| KR101646181B1 (ko) | 2015-08-18 | 2016-08-05 | 한양대학교 에리카산학협력단 | 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물 |
| EP4039699A1 (en) | 2015-12-23 | 2022-08-10 | ModernaTX, Inc. | Methods of using ox40 ligand encoding polynucleotides |
| US20190241658A1 (en) | 2016-01-10 | 2019-08-08 | Modernatx, Inc. | Therapeutic mRNAs encoding anti CTLA-4 antibodies |
| AR108280A1 (es) * | 2016-05-05 | 2018-08-08 | Acraf | Composición oftálmica que comprende una combinación sinérgica de glucógeno y ácido hialurónico o sal del mismo |
| US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
| WO2018104538A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rna for treatment or prophylaxis of a liver disease |
| EP3592389B1 (en) | 2017-03-11 | 2025-05-07 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| EP3679140B1 (en) | 2017-09-08 | 2022-11-16 | MiNA Therapeutics Limited | Stabilized cebpa sarna compositions and methods of use |
| AU2018330495A1 (en) | 2017-09-08 | 2020-03-26 | Mina Therapeutics Limited | Stabilized hnf4a sarna compositions and methods of use |
| JP2021501753A (ja) * | 2017-11-03 | 2021-01-21 | ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 徐放性ナノキャリア製剤を形成するための疎水性イオン対化およびフラッシュナノ沈殿 |
| US11566246B2 (en) | 2018-04-12 | 2023-01-31 | Mina Therapeutics Limited | SIRT1-saRNA compositions and methods of use |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| WO2020208361A1 (en) | 2019-04-12 | 2020-10-15 | Mina Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| US11987791B2 (en) | 2019-09-23 | 2024-05-21 | Omega Therapeutics, Inc. | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression |
| CN114391040A (zh) | 2019-09-23 | 2022-04-22 | 欧米茄治疗公司 | 用于调节载脂蛋白b(apob)基因表达的组合物和方法 |
| CN116096886A (zh) | 2020-03-11 | 2023-05-09 | 欧米茄治疗公司 | 用于调节叉头框p3(foxp3)基因表达的组合物和方法 |
| GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| EP4314292A1 (en) | 2021-03-26 | 2024-02-07 | MiNA Therapeutics Limited | Tmem173 sarna compositions and methods of use |
| WO2023283359A2 (en) | 2021-07-07 | 2023-01-12 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| US20240342206A1 (en) | 2021-07-30 | 2024-10-17 | CureVac SE | mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES |
| WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
| GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
| WO2023144193A1 (en) | 2022-01-25 | 2023-08-03 | CureVac SE | Mrnas for treatment of hereditary tyrosinemia type i |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
| EP4634388A1 (en) | 2022-12-14 | 2025-10-22 | Providence Therapeutics Holdings Inc. | Compositions and methods for infectious diseases |
| WO2024134199A1 (en) | 2022-12-22 | 2024-06-27 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
| WO2024243438A2 (en) | 2023-05-23 | 2024-11-28 | Omega Therapeutics, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5186941A (en) * | 1983-05-06 | 1993-02-16 | Vestar, Inc. | Vesicle formulation for the controlled release of therapeutic agents |
| US4855132A (en) * | 1986-02-25 | 1989-08-08 | S R I International | Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product |
| US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
| US6106858A (en) * | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
| HU230454B1 (hu) * | 1998-11-02 | 2016-07-28 | Alkermes Pharma Ireland Limited | Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény |
| GB0009735D0 (en) * | 2000-04-19 | 2000-06-07 | Zeneca Ltd | Formulation |
| CA2313659A1 (en) * | 2000-07-06 | 2002-01-06 | Barry J. Barclay | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
| ATE320792T1 (de) * | 2000-09-28 | 2006-04-15 | Chiron Corp | Mikropartikel zur verabreichung von heterologen nukleinsäure |
| US20030215394A1 (en) * | 2002-05-17 | 2003-11-20 | Short Robert E. | Microparticles having a matrix interior useful for ultrasound triggered delivery of drugs into the bloodstream |
| JP4038585B2 (ja) * | 2002-06-03 | 2008-01-30 | 宮崎県 | 固体脂マイクロカプセルおよびその製造方法 |
| US7060299B2 (en) * | 2002-12-31 | 2006-06-13 | Battelle Memorial Institute | Biodegradable microparticles that stabilize and control the release of proteins |
| US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
| EP1679065A1 (en) * | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
| US20080305161A1 (en) * | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
| US8765181B2 (en) * | 2005-09-09 | 2014-07-01 | Beijing Diacrid Medical Technology Co., Ltd | Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids |
| CA2631714C (en) * | 2005-12-02 | 2014-09-16 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| DE102006013531A1 (de) * | 2006-03-24 | 2007-09-27 | Lts Lohmann Therapie-Systeme Ag | Polylactid-Nanopartikel |
| CN101965212A (zh) * | 2007-12-05 | 2011-02-02 | 眼门药品公司 | 通过离子电渗疗法递送siRNA的方法 |
| EP3067048B1 (en) * | 2007-12-07 | 2018-02-14 | GlaxoSmithKline Biologicals SA | Compositions for inducing immune responses |
| FR2935901A1 (fr) * | 2008-09-16 | 2010-03-19 | Inst Curie | Polymersome asymetrique stimulable. |
| WO2010138193A2 (en) * | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| SMT202000093T1 (it) * | 2009-06-16 | 2020-03-13 | Pfizer | Forme di dosaggio di apixaban |
-
2012
- 2012-03-23 EA EA201391392A patent/EA201391392A1/ru unknown
- 2012-03-23 EP EP12764409.4A patent/EP2694040A4/en not_active Withdrawn
- 2012-03-23 CA CA2830948A patent/CA2830948A1/en not_active Abandoned
- 2012-03-23 US US13/428,340 patent/US20120244222A1/en not_active Abandoned
- 2012-03-23 AU AU2012236937A patent/AU2012236937B2/en active Active
- 2012-03-23 JP JP2014502642A patent/JP6320912B2/ja active Active
- 2012-03-23 BR BR112013024655A patent/BR112013024655A2/pt not_active Application Discontinuation
- 2012-03-23 CN CN2012800146549A patent/CN103458879A/zh active Pending
- 2012-03-23 WO PCT/US2012/030314 patent/WO2012135010A2/en not_active Ceased
- 2012-03-23 KR KR1020137027777A patent/KR20140022025A/ko not_active Ceased
- 2012-03-23 MX MX2013010972A patent/MX366228B/es active IP Right Grant
-
2017
- 2017-05-17 AU AU2017203307A patent/AU2017203307A1/en not_active Abandoned
- 2017-12-01 JP JP2017231391A patent/JP2018076331A/ja active Pending
-
2022
- 2022-07-28 US US17/815,877 patent/US20230139671A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018076331A5 (enExample) | ||
| JP2014511847A5 (enExample) | ||
| US20230139671A1 (en) | Osmotic mediated release synthetic nanocarriers | |
| Qing et al. | Natural and engineered bacterial outer membrane vesicles | |
| ES2762631T3 (es) | Composiciones a base de nanopartículas | |
| Henriksen-Lacey et al. | Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response | |
| Kaur et al. | Pegylation of DDA: TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses | |
| CN101287742B (zh) | 基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物 | |
| US20230381306A1 (en) | Structure-Function Relationships in the Development of Immunotherapeutic Agents | |
| KR20180096591A (ko) | 광범위 인플루엔자 바이러스 백신 | |
| JP2014514275A5 (enExample) | ||
| KR20130108988A (ko) | 애주번트가 결합된 합성 나노담체의 용량 선택 | |
| CN101874112A (zh) | 特别是作为免疫刺激剂/佐剂的式(Ⅰ):G1XmGn或式(Ⅱ):C1XmCn的核酸 | |
| ES2908826T3 (es) | Composiciones de flagelina de entrecoccus para su uso en terapia | |
| KR20160055863A (ko) | 면역 부활 활성을 갖는 올리고뉴클레오티드 함유 복합체 및 그 용도 | |
| US8383598B2 (en) | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | |
| Manju et al. | Nanovaccines to combat drug resistance: The next-generation immunisation | |
| US20240024451A1 (en) | Compositions and methods for improved vaccination | |
| Tomai et al. | TLR agonists as vaccine adjuvants | |
| US20210220454A1 (en) | Design of immunostimulatory protein-core spherical nucleic acids | |
| EP4304606A1 (en) | Polysaccharide adjuvants for virus vaccines | |
| Twilhaar et al. | General discussion and future prospects | |
| Brown et al. | Nucleic Acids as Adjuvants | |
| Brohlin | Polymeric Encapsulation of Vaccines for Enhanced Immunogenicity |